Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 11/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132908 | 0.88 | FBP1 (0.38) | FBP1HTTTHRATHRBTLR7 | |
| SCHEMBL4142711 | 0.87 | FBP1 (0.39) | FBP1HTTHSD17B10GAA | |
| SCHEMBL14283764 | 0.86 | HTT (0.46) | FBP1HTTTLR7HSD17B10GAA | |
| SCHEMBL4129371 | 0.84 | FBP1 (0.40) | FBP1HTTTLR7HSD17B10GAA | |
| SCHEMBL4135187 | 0.84 | FBP1 (0.40) | FBP1HTTTLR7HSD17B10GAA | |
| SCHEMBL4137826 | 0.84 | FBP1 (0.40) | FBP1HTTTLR7HSD17B10GAA | |
| SCHEMBL4129961 | 0.82 | FBP1 (0.35) | FBP1 | |
| SCHEMBL4121585 | 0.81 | HTT (0.40) | FBP1HTTHSD17B10GAA | |
| SCHEMBL4129034 | 0.81 | FBP1 (0.39) | FBP1HTTTLR7GAA | |
| SCHEMBL4134573 | 0.80 | FBP1 (0.45) | FBP1HTTHSD17B10GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | JIANG TAO (US) | 2005-01-06 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885HTT 4353/4885THRA 1752/4885 |
| US-20050004077-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885HTT 4308/4885THRA 1730/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885HTT 4308/4885THRA 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.